Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial

BACKGROUND: Thymic epithelial tumors (TETs) are rare malignancies and the treatment options are limited. We aimed to evaluate the efficacy and safety of apatinib, an angiogenesis inhibitor, in advanced TETs. METHODS: This was an open-label, single-arm, phase II trial at three centers in China. Patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Zhengbo, Lou, Guangyuan, Wang, Yina, Yang, Zhiping, Wang, Wenxian, Ji, Yongling, Chen, Shiqing, Xu, Chunwei, Hu, Xiao, Zhang, Yiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088066/
https://www.ncbi.nlm.nih.gov/pubmed/35534877
http://dx.doi.org/10.1186/s12916-022-02361-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088066/
https://www.ncbi.nlm.nih.gov/pubmed/35534877
http://dx.doi.org/10.1186/s12916-022-02361-w

Ejemplares similares